Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5786736 | 0.84 | ALDH1A1 (0.46) | HPGDKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5787312 | 0.83 | HPGD (0.41) | HPGDKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL14019129 | 0.78 | KDM4E (0.48) | HPGDKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4928638 | 0.78 | YTHDC1 (0.43) | HPGDKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4753476 | 0.78 | CHUK (0.51) | HPGDKDM4EALDH1A1ADORA2ASMN1; SMN2 | |
| SCHEMBL14441710 | 0.76 | IDO1 (0.42) | HPGDADORA2ANPSR1ADORA1IDO1 | |
| SCHEMBL22911122 | 0.74 | CHUK (0.43) | CHUKDHFR | |
| SCHEMBL18040266 | 0.73 | DPP4 (0.49) | HPGDKDM4EALDH1A1ADORA2ASMN1; SMN2 | |
| SCHEMBL26708031 | 0.72 | KDM4E (0.61) | HPGDKDM4EALDH1A1ADORA2ASMN1; SMN2 | |
| SCHEMBL16475309 | 0.72 | ALDH1A1 (0.56) | HPGDKDM4EALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3546462-B1 | NOVEL OXOISOQUINOLINE DERIVATIVE | CARNA BIOSCIENCES INC (JP) | 2024-01-03 | — | — | EP | disclosed |
| CN-109963852-B | Oxoisoquinoline derivatives | 卡尔那生物科学株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-10793575-B2 | Oxoisoquinoline derivatives | CARNA BIOSCIENCES, INC. (JP) | 2020-10-06 | — | — | US | disclosed |
| EP-3546462-A1 | NOVEL OXOISOQUINOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2019-10-02 | — | — | EP | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-7148228-B2 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-06-02 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HPGD 138/4885KDM4E 4076/4885ALDH1A1 1852/4885 |
| US-10793575-B2 | Oxoisoquinoline derivatives | BCL6, BCL6B, BCL3 | HPGD 2334/4885KDM4E 875/4885ALDH1A1 2504/4885 |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HPGD 138/4885KDM4E 4076/4885ALDH1A1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.